All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-03-27.
From the record
Stoke Therapeutics, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2022-02-17); an auditor change (8-K item 4.01, the latest 2026-03-27) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+145.8% a year over 4 filed years; profitable in 0 of 4.
From the record
Stoke Therapeutics, Inc.'s 4 filed years say what it did: revenue went from $12 million in fiscal 2022 to $184 million in fiscal 2025, up 145.8% a year; it rose in 2 of 3 years; the deepest fall was 29% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 5.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Stoke Therapeutics, Inc.'s shareholder treatment is put at 5.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 44% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -2%: lost 2¢ per shareholder dollar. Leverage 16%: owes 16¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Stoke Therapeutics, Inc. lost about 2 cents for every dollar of shareholders' money. Leverage: it owed about 16 cents per dollar of assets, and net share issuance: its share count grew 9.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 21% of 315 in its family; net margin -3.7%.
From the record
Stoke Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $184 million in fiscal 2025 ranks in the top 29% by size; a net margin of -3.7% ranks in the top 26%; revenue growth of 145.8% a year over the last 3 filed years ranks in the top 9% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 45% of 315 in its family for leadership; chief executive since 2025.
From the record
Stoke Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Smith, Ian F (Chief Executive Officer, as filed), filing under that title since 2025-03-20, 1.7 years (bottom 21% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 6.4 years (top 34%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 49%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 41% of 273 in its family for room to expand.
From the record
Stoke Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $84 million against no long-term debt tagged leaves 20.1% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is 24.4% of revenue (top 10%); research spending of 74.8% of revenue (bottom 46%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 36% of 306 in its family for growth drivers.
From the record
Stoke Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 145.8% a year over the last three filed years against 145.8% over all 4, speeding up (top 40% of its family); the newest year grew 405.1% (top 8%); research spending grew 21% a year (top 22%); capital spending grew -44.7% a year (bottom 25%) (its annual reports). Stoke Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 15% of 233 in its family for expectations against reality.
From the record
Stoke Therapeutics, Inc.'s newest year against its own record: revenue of $184 million in fiscal 2025 came in 194% above the $63 million its prior three years' pace pointed to (top 12% of its family); net income of $7 million against a prior three-year average of $98 million (top 18%); a net margin of -3.7% against losses larger than its revenue before (top 16%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made